EUVIMEDDécouvrir EUVIMED
CrossrefCarte d’information

A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow‐Up

Abhinav L. Talekar, Prasad K. Musale, Gayatri S. Chaudhari, Tayaba M. H. Silotry, William F. Waggoner

International Journal of Paediatric Dentistry · 2025-07 · 35 (4) · 763-773

DOI: 10.1111/ipd.13288 ↗
RésuméRéférences bibliographiques

Résumé

ABSTRACT Background In recent times, bioceramic calcium silicates have gained attention due to high success rates with pulpotomy in primary teeth. Aims To evaluate and compare the clinical and radiographic outcomes of three different bioceramic calcium silicate cements in vital deciduous teeth treated with pulpotomies over a period of 24 months. Design Children aged 4–9 years, with deep dentinal caries (ICDAS 4–6) in primary molars, having no history of spontaneous pain or signs of non‐vitality were included in the study. Following clinical and radiographic evaluation 117 primary molars diagnosed as having reversible pulpitis received pulpotomy treatment, after randomly being assigned into three groups based on the bioceramic calcium silicate medicament used: a pre‐mixed syringe‐loaded MTA putty (NeoPUTTY); a traditional powder‐liquid hand mix MTA material (NeoMTA Plus), and a precapsulated, trituration mixed material (Biodentine). Clinical and radiographic evaluation was done at 6, 12, 18 and 24 months. Results The cumulative clinical and radiographic success for NeoPUTTY was 92%, NeoMTA Plus 97% and for Biodentine 95% and 89%, respectively, after 24 months follow‐up. Conclusion The clinical and radiographic success rates of all three bioceramic calcium silicate cements were found to be high, with no significant differences over a period of 24 months. Trial Registration Clinical trial registration number: CTRI/2021/03/031655

Des connaissances adaptées à votre travail.

D’un démarrage gratuit à la Research Suite complète, en passant par la recherche bibliographique personnelle.

Voir les tarifs →

Tous les textes intégraux sont-ils inclus ?

Non. Notices, résumés et textes intégraux sont des contenus distincts. La disponibilité dépend de la source, de l’accès ouvert et de vos licences. Une offre EUVIMED ne remplace pas des droits supplémentaires auprès des éditeurs.

Voir les tarifs →